15 months child healthy growth
Reading File
Finding Sources
Finding Sources
Searching the Web
15 month old child healthy growth milestones development 2024
Reading File
Finding Sources
Reading Web Page
https://www.cdc.gov/act-early/milestones/15-months.html
Finding Sources
Finding Sources
Cataract best surgery
Reading File
Finding Sources
Finding Sources
Searching the Web
best cataract surgery type phacoemulsification vs FLACS 2024 2025 comparison outcomes
Clareon monofocal lens
Finding Sources
Finding Sources
Searching the Web
Clareon monofocal IOL Alcon clinical outcomes PCO glistening 2024 2025
Searching PubMed
Clareon monofocal intraocular lens outcomes
Reading Article
PMID: 41164804
Reading Article
PMID: 39624257
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC10964544
Here is a thorough clinical overview of the Clareon Monofocal IOL based on published studies and manufacturer data:
Clareon Monofocal IOL (Alcon) - Clinical Overview
What It Is
The Clareon is a 1-piece, foldable, aspheric, hydrophobic acrylic intraocular lens made by Alcon. It is the next-generation evolution of Alcon's well-established AcrySof SN60WF platform, built on the same optical design but with a new proprietary material: hydroxyethyl-methacrylate (HEMA) with a UV blocker and a blue-light chromophore.
Key Design Features
| Feature | Details |
|---|---|
| Material | Hydrophobic acrylic HEMA-based |
| Optic | Aspheric, -0.2 µm aberration correction (same as AcrySof) |
| Optic diameter | 6 mm fully usable |
| Haptics | STABLEFORCE haptics - superior axial and rotational stability |
| Edge design | Proprietary precision edge - reduces PCO and edge glare |
| UV/Blue light filter | Yes - built in |
| Delivery systems | Monarch IV (manual, reusable) or AutonoMe (automated, single-use) |
Why It Was Developed (vs. AcrySof)
The main driver was glistening - water-filled nanovacuoles that form in hydrophobic acrylic lenses over time. The older AcrySof material was associated with clinically measurable glistening in a portion of patients. The Clareon material was reformulated to virtually eliminate this.
Clinical Outcomes - What the Studies Show
1. Long-Term Real-World Study ("Clarte Study") - 191 eyes, 3-year follow-up
Published in BMC Ophthalmology (2024):
- Mean CDVA at 3 years: 0.003 logMAR (essentially 20/20 corrected)
- Mean UDVA at 3 years: 0.075 logMAR
- 50% of patients achieved 20/20 uncorrected; 75% achieved 20/25 or better
- Glistening-free: 95.3% of eyes at 3 years - only 4.7% had any glistening (all grade 1-2, none visually significant)
- PCO requiring Nd:YAG: 4.7% at 3 years (identical to the predecessor AcrySof rate)
2. Canadian Real-World Study (Tran et al., 2025) - 85 eyes, AutonoMe delivery
Published in Clinical Ophthalmology (PMID: 41164804):
- Mean spherical equivalent at 3 months: +0.09 D (near emmetropia)
- Mean UDVA: 0.13 logMAR; BCDVA: 0.02 logMAR
- Zero glistenings detected at 3 or 12 months
- Stable refraction from 1 to 12 months with no device-related complications
3. US Prospective Study (Christenbury & Hall, 2024) - 56 eyes, Monarch IV delivery
Published in Clinical Ophthalmology (PMID: 39624257):
- Binocular distance UDVA at 3 months: 0.03 logMAR (~20/21)
- Intermediate vision (66 cm): 98% of eyes achieved 20/25 or better
- Patient satisfaction: 88%
- Smooth in-the-bag delivery in 89% of eyes
Glistening Performance - What Makes Clareon Stand Out
Alcon's own 9-year data (n=20) and 3-year data (n=138) report zero glistenings (Miyata grade 0) in long-term clinical studies. In vitro testing shows the Clareon material has among the lowest levels of glistenings, subsurface nanoglistenings (SSNGs), and surface haze compared to leading competitor lenses.
Clareon vs. AcrySof SN60WF - Key Differences
| AcrySof SN60WF | Clareon | |
|---|---|---|
| Material | Hydrophobic acrylic | New HEMA hydrophobic acrylic |
| Glistening rate | Measurable in studies | Near zero (0-4.7% at 3 yrs, all low grade) |
| Delivery | Various injectors | Monarch IV or AutonoMe |
| PCO rate (3 yr) | ~4.7% | ~4.7% (comparable) |
| Optic design | -0.2 µm aspheric | Same (-0.2 µm aspheric) |
| Preloaded option | No | Yes (AutonoMe is fully automated/preloaded) |
Clareon vs. Johnson & Johnson Eyhance (Competing Monofocal)
A clinical study of 310 patients (155 per group) found no significant difference in range of vision between Clareon and the J&J Eyhance monofocal. Both deliver comparable distance and functional intermediate vision.
Available Variants in the Clareon Family
- Clareon Monofocal - standard distance focus
- Clareon Toric - corrects astigmatism simultaneously
- Clareon PanOptix - trifocal (near/intermediate/distance)
- Clareon Vivity - extended depth of focus (EDOF)
Who Is It Best For?
- Patients wanting excellent distance vision with spectacles for near
- Patients concerned about long-term optical clarity (worried about lens clouding)
- Surgeons who prefer the AutonoMe automated delivery system for consistent implantation
- Those with astigmatism (Toric version available)
- Patients with complex ocular history where premium/multifocal IOLs are contraindicated
Bottom Line
The Clareon Monofocal delivers outcomes essentially equivalent to the AcrySof SN60WF in terms of visual acuity and PCO rates, but with a meaningfully improved glistening profile over long-term follow-up. The redesigned delivery systems (especially AutonoMe) add consistency to implantation. For surgeons already familiar with Alcon IOLs, it is a straightforward upgrade with no downside in clinical performance. - Clarte Study, BMC Ophthalmology 2024; Tran et al., Clinical Ophthalmology 2025 (PMID: 41164804)
This is a shared conversation. Sign in to Orris to start your own chat.